ClinicalTrials.gg
CompletedNCT05115942Updated Dec 20, 2024

Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

A Phase 3 interventional study of Hydronidone capsules and The placebo capsules in Liver Fibrosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 44 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Enrollment
33rd of 127
248 · median 120
Started
2021
with 12 others
Phase 3
9 of 214
4 open now
Registered
122nd of 214
by date
Lead sponsor
6 of 214
Beijing Continent Pharmaceutical Co, Ltd.

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 33rd largest by enrollment of the 127 interventional ones that give a count, is one of 13 that started in 2021, is one of 9 in phase 3, and was the 122nd registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study.

The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of chronic hepatitis B liver fibrosis.

Read the detailed description

248 patients with chronic viral hepatitis B liver fibrosis were enrolled in this 52-week study, and randomized into hydronidone or placebo group. Each group has 124 patients. Both groups were treated with entecavir antiviral basic therapy.

03

Conditions studied

  • Liver Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age from 18 to 65 years old (including 18 and 65 years old, based on the time of signing the written ); gender is not limited.
  2. History of chronic and/or hepatitis B surface antigen (HBsAg) positive≥6 months.
  3. Percutaneous liver confirmed liver fibrosis (Ishak score ≥3).
  4. Positive HBV DNA.
  5. \< 8 x (standard upper limit).
  6. No antiviral therapy with interferon and/or nucleoside analogues within 3 months prior to enrollment.
  7. 3 months before inclusion, he/she had not received any of the following proprietary Chinese medicines that may have anti-fibrosis effects: Fuzheng Huayu Capsule (tablet), Anluo Huayu Pill, compound Bijiaruangan tablet, etc.
  8. The subject (or his/her sexual partner) had no pregnancy plan during the trial period and within 6 months after the trial, voluntarily used effective physical , and had no sperm or egg donation plan.
  9. Before the trial, they have understood the nature, significance, potential benefits, inconvenience and potential dangers of the trial in detail, and have voluntarily participated in the clinical trial, have good communication with the researchers, comply with the requirements of the whole study, and have signed a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Massive upper gastrointestinal hemorrhage within 3 months before enrolment.
  2. Total (TBiL) > 3×, or 3×ULN \< \< 8×ULN and TBiL > 2×ULN.
  3. AFP > 100 μg/L although there was no indication of liver cancer.
  4. (PLT) ≤60×109/L.
  5. Prothrombin activity (PTA) \< 50% or > 1.5.
  6. Imaging showed obvious space-occupying lesions in the liver, suggesting tumor.
  7. (BMI) > 30 kg/m2.
  8. Patients with decompensated liver cirrhosis and liver malignant tumor.
  9. Patients with chronic or non-viral (alcoholic, non-alcoholic, drug, etc.) chronic hepatitis.
  10. Serious diseases of cardiovascular, pulmonary, renal, endocrine, neurological and haematological systems, as well as mental disorders .
  11. Women who are pregnant and/or breastfeeding.
  12. Have participated in clinical trials of other drugs in the last 3 months.
  13. The Investigator considers that there are any conditions that may affect the subjects' or adherence to the study protocol, or participation in the study may affect the study results or their own safety.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Hydronidone group

    Patients were orally received hydronidone capsules,3 capsules each time, t.i.d. for 52 weeks.

    Drug: Hydronidone capsules

  • Placebo comparator
    The placebo group

    Patients were orally received placebo capsules,3 capsules each time, t.i.d. for 52 weeks.

    Drug: The placebo capsules

Interventions

  • After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.

    Also known as: F351

  • DrugThe placebo capsules

    After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.

    Also known as: N

06

What researchers measure

Primary outcomes

  1. Change in Ishak stage score of liver fibrosis by greater than or equal to 1 point after 52 weeks of treatment relative to baseline.

    Clinically, the liver pathology scoring system, Ishak system, is widely used make a detailed and accurate assessment of the degree of parenchymal fibrosis or cirrhosis of the nontumorous liver. Ishak system uses a scale of 7 stages (scores 0-6) for the degree of fibrosis; the higher the score, the higher degree the severity of the disease.

    Time frame: 52 weeks

Secondary outcomes

  1. Change in liver inflammation grade by greater than or equal to 1 grade after 52 weeks of treatment relative to baseline but with no progression of fibrosis.

    Scheuer score system is a liver pathology scoring system used for the diagnosis of liver inflammation and fibrosis pathology clinically; In the present trial, Scheuer system for scoring necroinflammatory activitt in chronic hepatitis will be used(G0-G4),the higher the score, the higher degree the severity of the disease.

    Time frame: 52 weeks

  2. Change in liver tissue inflammation grade by greater than or equal to 1 grade after 52 weeks of treatment relative to baseline.

    Scheuer score system is a liver pathology scoring system used for the diagnosis of liver inflammation and fibrosis pathology clinically; In the present trial, Scheuer system for scoring necroinflammatory activitt in chronic hepatitis will be used(G0-G4),the higher the score, the higher degree the severity of the disease.

    Time frame: 52 weeks

  3. Change in liver stiffness measurement values via transient elastography LSM (kPa)

    Change in liver stiffness measurement values via transient elastography LSM (kPa) values relative to baseline after 52 weeks of treatment.

    Time frame: Screening period/baseline and weeks 12, 24, 36, and 52 after treatment .

  4. Negative conversion (below the lower limit of detection) and the extent of decrease in HBV DNA

    Negative conversion (below the lower limit of detection) and the extent of decrease in HBV DNA after 52 weeks of treatment.

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  5. Normalization and the degree of improvement of the indicators of liver function ALT after 52 weeks of treatment.

    ALT is one of the indicators to assess liver function and detect liver damage. When hepatic cells are affected by injury or disease, ALT is released into the blood, resulting in elevated ALT levels in the blood.

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  6. Safety endpoints:Laboratory examination(AFP test)

    AFP test: the serum AFP will be detected.

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  7. Safety endpoints:AE

    Adverse events (AEs) refer to any adverse medical events that occur after the patient takes the study drug and can manifest as signs and symptoms, disease, or abnormal laboratory tests, but are not necessarily consequently related to the study drug. Information on AEs and Concomitant medications occurring in patients will be collected at the time points specified in the study schedule. AEs will be evaluated with reference to the Common Adverse Events Evaluation Criteria (NCI-CTCAE version 5.0).

    Time frame: 52 weeks

  8. Safety endpoints:Laboratory examination(Metabolic panel-AST)

    Metabolic panel: The panel includes aspartate aminotransferase (AST),which is one of the indicators to assess liver function and detect liver damage.

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  9. Safety endpoints:Laboratory examination(Metabolic panel-GGT)

    Metabolic panel: The panel includes gamma-glutamyl transpeptidase (GGT),which is one of the indicators to assess liver function .

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  10. Safety endpoints:Laboratory examination(Metabolic panel-ALP)

    Metabolic panel: The panel includes alkaline phosphatase (ALP),which is one of the indicators to assess liver function .

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  11. Safety endpoints:Laboratory examination(Metabolic panel-TP)

    Metabolic panel: The panel includes total protein (TP), which is one of the indicators to assess liver function .

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  12. Safety endpoints:Laboratory examination(Metabolic panel-A)

    Metabolic panel: The panel includes albumin (A) , which is one of the indicators to assess liver function .

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  13. Safety endpoints:Laboratory examination(Metabolic panel-TBiL)

    Metabolic panel: The panel includes total bilirubin (TBiL) , which is one of the indicators to assess liver function .

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

  14. Safety endpoints:Laboratory examination(Metabolic panel-DBiL)

    Metabolic panel: The panel includes direct bilirubin (DBiL) , which is one of the indicators to assess liver function .

    Time frame: Screening period/baseline and weeks 4, 8, 12, 24, 36, and 52 after treatment.

07

Study locations

44 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
    Hefei, Anhui, China
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing 100020, China
  • Beijing You 'an Hospital, Capital Medical University
    Beijing, Beijing, China
  • Tsinghua Changgeng Hospital, Beijing
    Beijing, Beijing, China
  • Peking University First Hospital
    Peking, Beijing, China
  • Chongqing Public Health Medical Treatment Center (Chongqing Infectious Disease Hospital)
    Chongqing, Chongqing, China
  • Chongqing Three Gorges Central Hospital
    Chongqing, Chongqing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • The First Affiliated Hospital of Fujian Medical University
    Fujian, Fujian, China
  • Xiamen Hospital of Traditional Chinese Medicine
    Xiamen, Fujian, China
  • Lanzhou university first hospital
    Lanzhou, Gansu, China
  • Shenzhen Third People's Hospital
    Shenzhen, Guangdong, China
  • Guizhou Provincial People's Hospital
    Guizhou, Guizhou, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou, China
  • Hangzhou Xixi Hospital (Hangzhou Sixth People's Hospital)
    Hangzhou, Hangzhou, China
  • The First Hospital of Hebei Medical University
    Hebei, Hebei, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
  • Henan Provincial People's Hospital
    Henan, Henan, China
  • The First Affiliated Hospital of Xinxiang Medical College
    Xinxiang, Henan, China
  • Zhengzhou Sixth People's Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Hunan University of Chinese Medicine
    Changsha, Hunan, China
  • The Second Xiangya Hospital, Central South University
    Changsha, Hunan, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of University of South China
    Yueyang, Hunan, China
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of SuZhou University
    Suzhou, Jiangsu, China
  • Taizhou People's Hospital
    Taizhou, Jiangsu, China
  • Wuxi Fifth People's Hospital
    Wuxi, Jiangsu, China
  • Affiliated Hospital of Xuzhou Medical College
    Xuzhou, Jiangsu, China
  • Zhenjiang Third People's Hospita
    Zhenjiang, Jiangsu, China
  • Nanchang Ninth Hospital (Nanchang Central Hospital)
    Nanchang, Jiangxi, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • First Hospital of Jilin University
    Jilin, Jilin, China
  • Second Hospital of Jilin University
    Jilin, Jilin, China
  • Yanbian University Affiliated Hospital
    Yanbian, Jilin, China
  • Shanghai General Hospital,Shanghai Jiao Tong University
    Shanghai, Shanghai 201620, China
  • Huashan Hospital affiliated to Fudan University
    Shanghai, Shanghai, China
  • Shanghai Jiao Tong University Affiliated Tongren Hospital
    Shanghai, Shanghai, China
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai, China
  • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University
    Luzhou, Sichuan, China
  • Ningbo Huamei Hospital, University of Chinese Academy of Sciences
    Ningbo, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Oct 2024, 33 months.

Of 25 phase 3 interventional studies under Liver Cirrhosis, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 82. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2021
First posted
Nov 10, 2021
StartActual
Dec 30, 2021
Primary completionActual
Oct 22, 2024
CompletionActual
Oct 22, 2024
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05115942
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Dec 30, 2021
Primary completion
Oct 22, 2024
Completion
Oct 22, 2024
Last update
Dec 20, 2024

Study contacts

Lungen Lu, Dr.
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Jun Cheng, Dr.
principal investigator · Beijing Ditan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion